Members

  First name: Vincent
  Last name: Jullien
  Function: University Professor and Hospital Practitioner
  Position: Head of the Pharmacology Unit, Paris Seine Saint-Denis Hospitals
  Email: vincent.jullien
._
_.
aphp.fr

Research interest


My main research area is the pharmacokinetics and pharmacodynamics of anti-infective drugs and the determination of their dose in patients in order to provide the optimal efficacy. I use population approaches to model the interindividual variability and to identify the relevant covariates on which the dose should be adapted. I also investigate the diffusion of anti-infective drugs from blood to the infected site.

Education

Degree

2014: Habilitation à Diriger les Recherches (Paris Descartes University)

2006 : PhD of Pharmacology (Paris Descartes University)

2002 : Pharm D (Paris Descartes University)

1999: DEA (Master) of Experimental and Clinical Pharmacology (Paris XI University)


Academic positions

2018-present : Professor of Pharmacology, Medical School, Sorbonne Paris Nord University; Head of the Pharmacology Unit, Paris Seine Saint-Denis University Hospitals

2013 – 2018: Associate Professor of Pharmacology, Medical School, Paris Descartes University; Pharmacology Department of Georges Pompidou European Hospital

2007 – 2013: Associate Professor of Pharmacology, Medical School, Paris Descartes University, Cochin – Saint Vincent de Paul hospital

2003 – 2007 : Assistant Professor of Pharmacology, Medical School, Paris Descartes University, Cochin – Saint Vincent de Paul hospital

2002 – 2003: Assistant Professor of Pharmacology, Medical School, Paris Descartes University, Hôpital Européen Georges Pompidou

1996 – 2002 : Resident in Pharmacy, Paris Descartes University


Research training (post doctoral)

January 2023-present: member of the team “Biostatistical Modelling, Clinical Investigation and Pharmacometrics in Infection Diseases” within the research unit UMR 1137 INSERM– “Infection . Antimicrobials. Modelling . Evolution”

2019 – 2022: member of the research unit “Molecular Mycology – CNRS-UMR 2000)

2006 – 2018: research unit UMR 663 INSERM “Childhood epilepsies and cerebral plasticity”


Exhaustive list of publications

2023


Diezi L, Dao K, Jullien V, Roussel-Maupetit C, Burton I, André P, Bardinet C, Rothuizen LE, Chtioui H, Manso-Silvan MA, Guittet C, Brunner-Ferber F, Vandenhende F, Chiron C, Granier LA, Buclin T
An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup.
Pharmacology Research & Perspectives 2023, 11, e01032.

Goulenok T, Seurat J, Selle AdL, Jullien V, Leflon-Guibout V, Grall N, Lescure FX, Lepeule R, Bertrand J, Fantin B, Burdet C, Lefort A
Pharmacokinetic interaction between rifampicin and clindamycin in staphylococcal osteoarticular infections.
International Journal of Antimicrobial Agents 2023, 62, 106885.

Baud FJ, Jullien V, Desnos-Ollivier M, Lamhaut L, Lortholary O
Caspofungin sequestration in a polyacrylonitrile-derived filter. Increasing the dose does not mitigate sequestration.
International Journal of Antimicrobial Agents 2023, 107007.

Goutelle S, Jullien V, Bru JP, Cattoir V, Gauzit R, Lesprit P, Lina G, Schramm F, Canoui E, Lepeule R
Defining standard and high dosages for β-lactam agents administered by intermittent, prolonged or continuous infusion: a PK/PD simulation study.
The Journal of Antimicrobial Chemotherapy 2023, dkad300.

Magréault S, Charbit J, Berkane N, Jaureguy F, Carbonnelle E, Cosson E, Jullien V, Bihan H
Usefulness of Therapeutic Drug Monitoring to Manage Clindamycin-Rifampicin Interaction in a Patient with Diabetic Foot Osteomyelitis.
Therapeutic Drug Monitoring 2023, 45, 703-706.

2022


Gueneau R, Joannard B, Haddad N, Alby F, Jullien V, Schlatter J, Cotteret C, Bougnoux ME, Lanternier F, Laroche L, Delliere S, Cisternino S, Lortholary O
Extensive dermatophytosis caused by terbinafine-resistant Trichophyton indotineae, successfully treated with topical voriconazole.
International Journal of Antimicrobial Agents 2022, 60, 106677.

Magréault S, Jaureguy F, Zahar JR, Méchaï F, Toinon D, Cohen Y, Carbonnelle E, Jullien V
Automated HPLC-MS/MS assay for the simultaneous determination of ten plasma antibiotic concentrations.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2022, 1211, 123496.

da Cunha MF, Pranke I, Sassi A, Schreiweis C, Moriceau S, Vidovic D, Hatton A, Carlon MS, Creste G, Berhal F, Prestat G, Freund R, Odolczyk N, Jais JP, Gravier-Pelletier C, Zielenkiewicz P, Jullien V, Hinzpeter A, Oury F, Edelman A, Sermet-Gaudelus I
Systemic bis-phosphinic acid derivative restores chloride transport in Cystic Fibrosis mice.
Scientific Reports 2022, 12, 6132.

Mimram L, Magréault S, Kerroumi Y, Salmon D, Kably B, Marmor S, Jannot AS, Jullien V, Zeller V
Population Pharmacokinetics of Orally Administered Clindamycin to Treat Prosthetic Joint Infections: A Prospective Study.
Antibiotics (Basel, Switzerland) 2022, 11, 1462.

Pajot O, Lakhal K, Lambert J, Gros A, Bruel C, Boulain T, Garot D, Das V, Timsit JF, Cerf C, Souweine B, Chaffaut C, Mentec H, Zahar JR, Mira JP, Jullien V
Empirical Antibiotic Therapy for Gram-Negative Bacilli Ventilator-Associated Pneumonia: Observational Study and Pharmacodynamic Assessment.
Antibiotics (Basel, Switzerland) 2022, 11, 1664.

2021


Comets E, Rodrigues C, Jullien V, Ursino M
Conditional Non-parametric Bootstrap for Non-linear Mixed Effect Models.
Pharmaceutical Research 2021, 38, 1057-1066.

Magréault S, Roy C, Launay M, Sermet-Gaudelus I, Jullien V
Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.
Clinical Pharmacokinetics 2021, 60, 409-445.

Baud FJ, Jullien V, Secrétan PH, Houzé P, Lamhaut L
Are we correctly treating invasive candidiasis under continuous renal replacement therapy with echinocandins? Preliminary in vitro assessment.
Anaesthesia, Critical Care & Pain Medicine 2021, 40, 100640.

Lemaitre F, Fily F, Foulquier JB, Revest M, Jullien V, Petitcollin A, Tattevin P, Tron C, Polard JL, Verdier MC, Comets E, Huten D, Arvieux C, Bellissant E, Laviolle B
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 2021, 142, 112053.

Zeller V, Magreault S, Heym B, Salmon D, Kitzis MD, Billaud E, Marmor S, Jannot AS, Salomon L, Jullien V
Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2021, 27, 1857.e1-1857.e7.

Tielli A, Jullien V, Pull L, Bouchaud O, Siriez JY
Unintentional artenimol/piperaquine overdose in two children occurring without evidence of subsequent cardiotoxicity.
International Journal of Antimicrobial Agents 2021, 57, 106347.

Pellicer A, Fernández R, Jullien V, Gleeson C, Bravo MC, Ortego PL, Sánchez L, Ybarra M, Rojas-Anaya H, Cabañas F, Koch A, Smith A, Rabe H, Neocirculation Consortium
Pharmacokinetic study (phase I-II) of a new dobutamine formulation in preterm infants immediately after birth.
Pediatric Research 2021, 89, 981-986.

Martino S, Arlet JB, Odièvre MH, Jullien V, Moras M, Hattab C, Lefebvre T, Gouya L, Ostuni MA, Lefevre SD, Le Van Kim C
Deficient mitophagy pathways in sickle cell disease.
British Journal of Haematology 2021, 193, 988-993.

Baud FJ, Jullien V, Abarou T, Pilmis B, Raphalen JH, Houzé P, Carli P, Lamhaut L
Elimination of fluconazole during continuous renal replacement therapy. An in vitro assessment.
The International Journal of Artificial Organs 2021, 44, 453-464.

Jemel S, Guillot J, Kallel K, Jouvion G, Brisebard E, Billaud E, Jullien V, Botterel F, Dannaoui E
In Vivo Efficacy of Voriconazole in a Galleria mellonella Model of Invasive Infection Due to Azole-Susceptible or Resistant Aspergillus fumigatus Isolates.
Journal of Fungi (Basel, Switzerland) 2021, 7, 1012.

2020


Eloy G, Lebeaux D, Launay M, Fernandez-Gerlinger MP, Billaud E, Douez E, Mainardi JL, Bouyer B, Jullien V
Influence of Renal Function and Age on the Pharmacokinetics of Levofloxacin in Patients with Bone and Joint Infections.
Antibiotics (Basel, Switzerland) 2020, 9, 401.

2019


Ounissi M, Rodrigues C, Bienayme H, Duhamel P, Pons G, Dulac O, Nabbout R, Chiron C, Jullien V
Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data.
Journal of Clinical Pharmacology 2019, 59, 177-188.

Rodrigues C, Chiron C, Ounissi M, Dulac O, Gaillard S, Nabbout R, Jullien V
Pharmacokinetic evaluation of vigabatrin dose for the treatment of refractory focal seizures in children using adult and pediatric data.
Epilepsy Research 2019, 150, 38-45.

Parize P, Mamez AC, Garcia-Hermoso D, Dumaine V, Poirée S, Kauffmann-Lacroix C, Jullien V, Lortholary O, Lanternier F
Successful Treatment of Saksenaea sp. Osteomyelitis by Conservative Surgery and Intradiaphyseal Incorporation of Amphotericin B Cement Beads.
Antimicrobial Agents and Chemotherapy 2019, 63, e01006-18.

Barde F, Billaud E, Goldwirt L, Horodyckid C, Jullien V, Lanternier F, Lesprit P, Limousin L, Cohen JF, Lortholary O
Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis.
Antimicrobial Agents and Chemotherapy 2019, 63, e01184-19.

Rouzaud C, Jullien V, Herbrecht A, Palmier B, Lapusan S, Morgand M, Guéry R, Dureault A, Danion F, Puget S, Goldwirt L, Lanternier F, Lortholary O
Isavuconazole Diffusion in Infected Human Brain.
Antimicrobial Agents and Chemotherapy 2019, 63, e02474-18.

Favrais G, Ursino M, Mouchel C, Boivin E, Jullien V, Zohar S, Saliba E
Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial.
BMJ open 2019, 9, e022739.

2018


Rodrigues C, Chhun S, Chiron C, Dulac O, Rey E, Pons G, Jullien V
A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.
European Journal of Clinical Pharmacology 2018, 74, 793-803.

Peigné S, Chhun S, Tod M, Rey E, Rodrigues C, Chiron C, Pons G, Jullien V
Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy.
Clinical Pharmacokinetics 2018, 57, 739-748.

Pilmis B, Garcia-Hermoso D, Alanio A, Catherinot E, Scemla A, Jullien V, Bretagne S, Lortholary O
Failure of voriconazole therapy due to acquired azole resistance in Aspergillus fumigatus in a kidney transplant recipient with chronic necrotizing aspergillosis.
American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2018, 18, 2352-2355.

Danion F, Jullien V, Rouzaud C, Abdel Fattah M, Lapusan S, Guéry R, Bigé N, Morgand M, Pallet N, Lanternier F, Lortholary O
Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?.
Antimicrobial Agents and Chemotherapy 2018, 62, e00705-18.

Launay M, Roux A, Beaumont L, Douvry B, Lecuyer L, Douez E, Picard C, Grenet D, Jullien V, Boussaud V, Guillemain R, Billaud EM
Posaconazole Tablets in Real-Life Lung Transplantation: Impact on Exposure, Drug-Drug Interactions, and Drug Management in Lung Transplant Patients, Including Those with Cystic Fibrosis.
Antimicrobial Agents and Chemotherapy 2018, 62, e02061-17.

Ali AM, Penny MA, Smith TA, Workman L, Sasi P, Adjei GO, Aweeka F, Kiechel JR, Jullien V, Rijken MJ, McGready R, Mwesigwa J, Kristensen K, Stepniewska K, Tarning J, Barnes KI, Denti P, WWARN Amodiaquine PK Study Group
Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing.
Antimicrobial Agents and Chemotherapy 2018, 62, e02193-17.

Petit C, Samson A, Morita S, Ursino M, Guedj J, Jullien V, Comets E, Zohar S
Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies.
Statistical Methods in Medical Research 2018, 27, 1860-1877.

2017


Guet-Revillet H, Tomini E, Emirian A, Join-Lambert O, Lécuyer H, Zahar JR, Jullien V
Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
International Journal of Antimicrobial Agents 2017, 49, 62-66.

Toussaint B, Lanternier F, Woloch C, Fournier D, Launay M, Billaud E, Dannaoui E, Lortholary O, Jullien V
An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2017, 1046, 26-33.

Duhamel P, Ounissi M, Le Saux T, Bienayme H, Chiron C, Jullien V
Determination of the R(-) and S(+)-enantiomers of vigabatrin in human plasma by ultra-high-performance liquid chromatography and tandem mass-spectrometry.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2017, 1070, 31-36.

Spire B, Nait-Ighil L, Pugliese P, Poizot-Martin I, Jullien V, Marcelin AG, Billaud E
Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING.
HIV clinical trials 2017, 18, 1-16.

Jullien V, Azoulay E, Schwebel C, Le Saux T, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet JL, Bruneel F, Cour M, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou JC, Foucrier A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Wolff M, Timsit JF, EMPIRICUS Trial Study Group
Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
The Journal of Antimicrobial Chemotherapy 2017, 72, 181-189.

Jullien V, Azoulay E, Schwebel C, Le Saux T, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet JL, Bruneel F, Cour M, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou JC, Foucrier A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Wolff M, Timsit JF, ETSG
Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
The Journal of Antimicrobial Chemotherapy 2017, 72, 181-189.

Pilmis B, Coignard-Biehler H, Rouzaud C, Jullien V, Lanternier F, Lortholary O
Acute reversible pancreatitis induced by posaconazole.
The Journal of Antimicrobial Chemotherapy 2017, 72, 628-630.

Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S
Drug adherence in hypertension: from methodological issues to cardiovascular outcomes.
Journal of Hypertension 2017, 35, 1133-1144.

Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S
Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients.
Journal of Hypertension 2017, 35, 1891-1898.

Rodrigues C, Chiron C, Rey E, Dulac O, Comets E, Pons G, Jullien V
Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
British Journal of Clinical Pharmacology 2017, 83, 2695-2708.

Hamdidouche I, Jullien V, Laurent S, Azizi M
Detecting Nonadherence to Antihypertensive Treatment: Any Time, Anywhere?.
Hypertension (Dallas, Tex.: 1979) 2017, 70, 257-258.

Pilmis B, Jullien V, Tabah A, Zahar JR, Brun-Buisson C
Piperacillin-tazobactam as alternative to carbapenems for ICU patients.
Annals of Intensive Care 2017, 7, 113.

2016


Timsit JF, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet JL, Bruneel F, Argaud L, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou JC, Foucrier A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Maubon D, Jullien V, Wolff M, EMPIRICUS Trial Group
Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
JAMA 2016, 316, 1555-1564.

Timsit JF, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet JL, Bruneel F, Argaud L, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou JC, Foucrier A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Maubon D, Jullien V, Wolff M, ETG
Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
JAMA 2016, 316, 1555-1564.

Jullien V, Pressler RM, Boylan G, Blennow M, Marlow N, Chiron C, Pons G, NEMO Consortium Neonatal Seizure Treatment With Medication Off-Patent
Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures.
Journal of Clinical Pharmacology 2016, 56, 284-290.

Join-Lambert O, Coignard-Biehler H, Jais JP, Delage M, Guet-Revillet H, Poirée S, Duchatelet S, Jullien V, Hovnanian A, Lortholary O, Nassif X, Nassif A
Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients.
The Journal of Antimicrobial Chemotherapy 2016, 71, 513-520.

Crabol Y, Catherinot E, Veziris N, Jullien V, Lortholary O
Rifabutin: where do we stand in 2016?.
The Journal of Antimicrobial Chemotherapy 2016, 71, 1759-1771.

de Kerviler E, Maravilla K, Meder JF, Naggara O, Dubourdieu C, Jullien V, Desché P
Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.
Investigative Radiology 2016, 51, 544-551.

Azizi M, Pereira H, Hamdidouche I, Gosse P, Monge M, Bobrie G, Delsart P, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Girerd X, Michel Halimi J, Zannad F, Ormezzano O, Vaïsse B, Herpin D, Ribstein J, Chamontin B, Mourad JJ, Ferrari E, Plouin PF, Jullien V, Sapoval M, Chatellier G, DENERHTN Investigators
Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial.
Circulation 2016, 134, 847-857.

Otienoburu SD, Maïga-Ascofaré O, Schramm B, Jullien V, Jones JJ, Zolia YM, Houzé P, Ashley EA, Kiechel JR, Guérin PJ, Le Bras J, Houzé S
Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.
Malaria Journal 2016, 15, 452.

2015


Curis E, Pestre V, Jullien V, Eyrolle L, Archambeau D, Morand P, Gatin L, Karoubi M, Pinar N, Dumaine V, Nguyen Van JC, Babinet A, Anract P, Salmon D
Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections.
Infection 2015, 43, 473-481.

Jullien V, Chhun S, Rey E, Dulac O, Tod M, Chiron C, Pons G
Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid.
Clinical Pharmacokinetics 2015, 54, 527-536.

Pressler RM, Boylan GB, Marlow N, Blennow M, Chiron C, Cross JH, de Vries LS, Hallberg B, Hellström-Westas L, Jullien V, Livingstone V, Mangum B, Murphy B, Murray D, Pons G, Rennie J, Swarte R, Toet MC, Vanhatalo S, Zohar S, NEonatal seizure treatment with Medication Off-patent (NEMO) consortium
Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial.
The Lancet. Neurology 2015, 14, 469-477.

Pressler RM, Boylan GB, Marlow N, de Vries LS, Blennow M, Chiron C, Cross JH, Hallberg B, Hellström-Westas L, Jullien V, Mangum B, Murphy B, Murray D, Pons G, Rennie J, Toet MC, Zohar S, NEMO consortium (NEonatal seizure treatment with Medication Off-patent)
Bumetanide for neonatal seizures-back from the cotside.
Nature Reviews. Neurology 2015, 11, 724.

Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C
Antifungal drugs during pregnancy: an updated review.
The Journal of Antimicrobial Chemotherapy 2015, 70, 14-22.

Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F
The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
The Pediatric Infectious Disease Journal 2015, 34, e63-70.

Petit C, Jullien V, Samson A, Guedj J, Kiechel JR, Zohar S, Comets E
Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults.
Antimicrobial Agents and Chemotherapy 2015, 60, 1481-1491.

WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study Group, Adjuik MA, Allan R, Anvikar AR, Ashley EA, Ba MS, Barennes H, Barnes KI, Bassat Q, Baudin E, Björkman A, Bompart F, Bonnet M, Borrmann S, Brasseur P, Bukirwa H, Checchi F, Cot M, Dahal P, D'Alessandro U, Deloron P, Desai M, Diap G, Djimde AA, Dorsey G, Doumbo OK, Espié E, Etard JF, Fanello CI, Faucher JF, Faye B, Flegg JA, Gaye O, Gething PW, González R, Grandesso F, Guerin PJ, Guthmann JP, Hamour S, Hasugian AR, Hay SI, Humphreys GS, Jullien V, Juma E, Kamya MR, Karema C, Kiechel JR, Kremsner PG, Krishna S, Lameyre V, Ibrahim LM, Lee SJ, Lell B, Mårtensson A, Massougbodji A, Menan H, Ménard D, Menéndez C, Meremikwu M, Moreira C, Nabasumba C, Nambozi M, Ndiaye JL, Nikiema F, Nsanzabana C, Ntoumi F, Ogutu BR, Olliaro P, Osorio L, Ouédraogo JB, Penali LK, Pene M, Pinoges L, Piola P, Price RN, Roper C, Rosenthal PJ, Rwagacondo CE, Same-Ekobo A, Schramm B, Seck A, Sharma B, Sibley CH, Sinou V, Sirima SB, Smith JJ, Smithuis F, Somé FA, Sow D, Staedke SG, Stepniewska K, Swarthout TD, Sylla K, Talisuna AO, Tarning J, Taylor WRJ, Temu EA, Thwing JI, Tjitra E, Tine RCK, Tinto H, Vaillant MT, Valecha N, Van den Broek I, White NJ, Yeka A, Zongo I
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data.
BMC medicine 2015, 13, 66.

Ounissi M, Benkirane A, Dempsey E, Soares R, Jullien V, Pons G, Chhun S
A review of potential pharmacogenetic effects on catecholamine responses.
Drug Metabolism Reviews 2015, 47, 558-564.

2014


Peigné S, Rey E, Le Guern ME, Dulac O, Chiron C, Pons G, Jullien V
Reassessment of stiripentol pharmacokinetics in healthy adult volunteers.
Epilepsy Research 2014, 108, 909-916.

Kloprogge F, Jullien V, Piola P, Dhorda M, Muwanga S, Nosten F, Day NPJ, White NJ, Guerin PJ, Tarning J
Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.
The Journal of Antimicrobial Chemotherapy 2014, 69, 3033-3040.

Jullien V, Valecha N, Srivastava B, Sharma B, Kiechel JR
Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria.
Malaria Journal 2014, 13, 187.

Ogutu B, Juma E, Obonyo C, Jullien V, Carn G, Vaillant M, Taylor WRJ, Kiechel JR
Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine.
Malaria Journal 2014, 13, 498.

Join-Lambert O, Ribadeau-Dumas F, Jullien V, Kitzis MD, Jais JP, Coignard-Biehler H, Guet-Revillet H, Consigny PH, Delage M, Nassif X, Lortholary O, Nassif A
Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination.
European journal of dermatology: EJD 2014, 24, 94-95.

2013


Pilmis B, Coignard-Biehler H, Jullien V, Hermine O, Touraine P, Lecuit M, Lortholary O
Iatrogenic Cushing's syndrome induced by posaconazole.
Antimicrobial Agents and Chemotherapy 2013, 57, 5727-5728.

Tarning J, Kloprogge F, Dhorda M, Jullien V, Nosten F, White NJ, Guerin PJ, Piola P
Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.
Antimicrobial Agents and Chemotherapy 2013, 57, 5096-5103.

Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, Sundaygar T, Zolia YM, Jones JJ, Comte E, Bruneel A, Branger M, Jullien V, Carn G, Kiechel JR, Ashley EA, Guérin PJ
Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia.
Malaria Journal 2013, 12, 250.

Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, Dhorda M, Boum Y, Sundaygar T, Zolia YM, Jones JJ, Comte E, Houzé P, Jullien V, Carn G, Kiechel JR, Ashley EA, Guérin PJ
Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial.
Malaria Journal 2013, 12, 251.

Timsit JF, Azoulay E, Cornet M, Gangneux JP, Jullien V, Vésin A, Schir E, Wolff M
EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial.
Trials 2013, 14, 399.

Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, Rosati A, Pons G, Tiddens H, Chabaud S, Caudri D, Ballot C, Kurbatova P, Castellan AC, Bajard A, Nony P, CRESim & Epi-CRESim Project Groups, Aarons L, Bajard A, Ballot C, Bertrand Y, Bretz F, Caudri D, Castellan C, Chabaud S, Cornu C, Dufour F, Dunger-Baldauf C, Dupont JM, Fisch R, Guerrini R, Jullien V, Kassaï B, Nony P, Ogungbenro K, Pérol D, Pons G, Tiddens H, Rosati A, Alberti C, Chiron C, Kurbatova P, Nabbout R
Experimental designs for small randomised clinical trials: an algorithm for choice.
Orphanet Journal of Rare Diseases 2013, 8, 48.

2012


Bouazza N, Pestre V, Jullien V, Curis E, Urien S, Salmon D, Tréluyer JM
Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis.
British Journal of Clinical Pharmacology 2012, 74, 971-977.

Tarning J, Chotsiri P, Jullien V, Rijken MJ, Bergstrand M, Cammas M, McGready R, Singhasivanon P, Day NPJ, White NJ, Nosten F, Lindegardh N
Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy.
Antimicrobial Agents and Chemotherapy 2012, 56, 5764-5773.

2011


Bouillon-Pichault M, Jullien V, Bazzoli C, Pons G, Tod M
Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.
Journal of Pharmacokinetics and Pharmacodynamics 2011, 38, 25-40.

Bouillon-Pichault M, Nabbout R, Chhun S, Rey E, Chiron C, Dulac O, Pons G, Jullien V
Topiramate pharmacokinetics in infants and young children: contribution of population analysis.
Epilepsy Research 2011, 93, 208-211.

Gerin M, Mahlaoui N, Elie C, Lanternier F, Bougnoux ME, Blanche S, Lortholary O, Jullien V
Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
Therapeutic Drug Monitoring 2011, 33, 464-466.

Rijken MJ, McGready R, Jullien V, Tarning J, Lindegardh N, Phyo AP, Win AK, Hsi P, Cammas M, Singhasivanon P, White NJ, Nosten F
Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria.
Antimicrobial Agents and Chemotherapy 2011, 55, 4338-4342.

Join-Lambert O, Coignard H, Jais JP, Guet-Revillet H, Poirée S, Fraitag S, Jullien V, Ribadeau-Dumas F, Thèze J, Le Guern AS, Behillil S, Leflèche A, Berche P, Consigny PH, Lortholary O, Nassif X, Nassif A
Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa.
Dermatology (Basel, Switzerland) 2011, 222, 49-58.

Loulergue P, Delaugerre C, Jullien V, Viard JP
HIV drug resistance on HAART despite an undetectable viral load.
Current HIV research 2011, 9, 623-624.

2010


Jullien V, Ogutu B, Juma E, Carn G, Obonyo C, Kiechel JR
Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.
Antimicrobial Agents and Chemotherapy 2010, 54, 2611-2617.

Guillot E, Sermet I, Ferroni A, Chhun S, Pons G, Zahar JR, Jullien V
Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
Pharmacotherapy 2010, 30, 1252-1258.

Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet AM
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.
Clinical Pharmacokinetics 2010, 49, 17-45.

Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet AM
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.
Clinical Pharmacokinetics 2010, 49, 17-45.

2009


Krivine A, Launay O, Firtion G, Finkielsztejn L, Jullien V, Rozenberg F, Pannier E
Does HIV-1 subtype D have a higher risk of vertical transmission than other HIV subtypes?.
The Journal of Infectious Diseases 2009, 199, 1553-1554; author reply 1554-1555.

Bouillon-Pichault M, Jullien V, Azria E, Pannier E, Firtion G, Krivine A, Compagnucci A, Taulera O, Finkielsztejn L, Chhun S, Pons G, Launay O, Treluyer JM
Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment.
The Journal of Antimicrobial Chemotherapy 2009, 63, 1223-1232.

Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G
Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Epilepsia 2009, 50, 1150-1157.

Lebeaux D, Lanternier F, Elie C, Suarez F, Buzyn A, Viard JP, Bougnoux ME, Lecuit M, Jullien V, Lortholary O
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.
Antimicrobial Agents and Chemotherapy 2009, 53, 5224-5229.

Lepercq J, Treluyer JM, Auger C, Raymond J, Rey E, Schmitz T, Jullien V
Evaluation of cefotaxime and desacetylcefotaxime concentrations in cord blood after intrapartum prophylaxis with cefotaxime.
Antimicrobial Agents and Chemotherapy 2009, 53, 2342-2345.

Royer B, Jullien V, Guardiola E, Heyd B, Chauffert B, Kantelip JP, Pivot X
Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment.
Clinical Pharmacokinetics 2009, 48, 169-180.

Bouillon-Pichault M, Jullien V, Piketty C, Viard JP, Morini JP, Chhun S, Krivine A, Salmon D, Dupin N, Weiss L, Lortholary O, Pons G, Launay O, Treluyer JM
A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients.
Antiviral Therapy 2009, 14, 923-929.

2008


Tod M, Lagneau F, Jullien V, Mimoz O
A physiological model to evaluate drug kinetics in patients with hemorrhagic shock followed by fluid resuscitation. Application to amoxicillin-clavulanate.
Pharmaceutical Research 2008, 25, 1431-1439.

Le Saux T, Chhun S, Rey E, Launay O, Weiss L, Viard JP, Pons G, Jullien V
Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2008, 865, 81-90.

Legrand T, Chhun S, Rey E, Blanchet B, Zahar JR, Lanternier F, Pons G, Jullien V
Simultaneous determination of three carbapenem antibiotics in plasma by HPLC with ultraviolet detection.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2008, 875, 551-556.

Tod M, Jullien V, Pons G
Facilitation of drug evaluation in children by population methods and modelling.
Clinical Pharmacokinetics 2008, 47, 231-243.

Blanchet B, Jullien V, Vinsonneau C, Tod M
Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.
Clinical Pharmacokinetics 2008, 47, 635-654.

2007


Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien V
Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2007, 852, 223-228.

Goldwirt L, Chhun S, Rey E, Launay O, Viard JP, Pons G, Jullien V
Quantification of darunavir (TMC114) in human plasma by high-performance liquid chromatography with ultra-violet detection.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2007, 857, 327-331.

Papaleo A, Warszawski J, Salomon R, Jullien V, Veber F, Dechaux M, Blanche S
Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir.
The Pediatric Infectious Disease Journal 2007, 26, 949-951.

Hirt D, Urien S, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Treluyer JM
Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.
British Journal of Clinical Pharmacology 2007, 64, 634-644.

2006


Giraud E, Rey E, Tréluyer JM, Pons G, Jullien V
Quantification of tipranavir in human plasma by high-performance liquid chromatography with UV detection.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2006, 830, 86-90.

Macassa E, Delaugerre C, Teglas JP, Jullien V, Tréluyer JM, Veber F, Rouzioux C, Blanche S
Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
The Pediatric Infectious Disease Journal 2006, 25, 809-814.

Jullien V, Urien S, Hirt D, Delaugerre C, Rey E, Teglas JP, Vaz P, Rouzioux C, Chaix ML, Macassa E, Firtion G, Pons G, Blanche S, Tréluyer JM
Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years.
Antimicrobial Agents and Chemotherapy 2006, 50, 3548-3555.

Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S
Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
Antimicrobial Agents and Chemotherapy 2006, 50, 2079-2086.

Hirt D, Urien S, Jullien V, Firtion G, Rey E, Pons G, Blanche S, Treluyer JM
Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.
Antimicrobial Agents and Chemotherapy 2006, 50, 910-916.

Jullien V, Lortholary O
[Pharmacokinetics-pharmacodynamics of antifungal drugs. Consequences for therapeutic drug monitoring].
Therapie 2006, 61, 209-217.

2005


Jullien V, Tréluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, Lillo-Le Louet A, Lescoat A, Dupin N, Salmon D, Pons G, Urien S
Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
Antimicrobial Agents and Chemotherapy 2005, 49, 3361-3366.

Jullien V, Urien S, Chappuy H, Dimet J, Rey E, Pons G, Blanche S, Tréluyer JM
Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.
Journal of Clinical Pharmacology 2005, 45, 257-264.

2004


Delaugerre C, Teglas JP, Treluyer JM, Vaz P, Jullien V, Veber F, Rouzioux C, Chaix ML, Blanche S
Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.
Journal of Acquired Immune Deficiency Syndromes (1999) 2004, 37, 1269-1275.

Chappuy H, Tréluyer JM, Jullien V, Dimet J, Rey E, Fouché M, Firtion G, Pons G, Mandelbrot L
Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women.
Antimicrobial Agents and Chemotherapy 2004, 48, 4332-4336.

2003


Elimadi A, Jullien V, Tillement JP, Morin D
S-15176 inhibits mitochondrial permeability transition via a mechanism independent of its antioxidant properties.
European Journal of Pharmacology 2003, 468, 93-101.

Jullien V, Tréluyer JM, Pons G, Rey E
Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2003, 785, 377-381.

Izzedine H, Launay-Vacher V, Jullien V, Aymard G, Duvivier C, Deray G
Pharmacokinetics of tenofovir in haemodialysis.
Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 2003, 18, 1931-1933.